BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$67.94
+2.33%Year over year
Reported trailing growth
- Revenue
- +202.4%
- EBITDA
- +5.0%
- EBIT
- +17.2%
- EPS
- +12.5%
- Free cash flow
- +34.1%
- Operating cash flow
- +33.8%
Forward estimates
Based on analyst estimates
- Revenue
- +102.2%
- EBITDA
- +91.6%
- EPS
- +71.7%
Three-year CAGR
- Revenue
- +86.3%
- EBITDA
- -54.9%
- EBIT
- +4.0%
- Net income
- -36.1%
- EPS
- -31.6%
- Free cash flow
- +14.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026